Searched for
MOLECULE VENTURES
Avammune’s big bet: Why the future of cancer treatment may come in a pillAs global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...- Japanese biotech developing tooth-regrowing drug raises $5.3 million to advance human trialsToregem BioPharma has secured $5.3 million to advance its experimental tooth-regeneration drug, TRG035, into Phase II clinical trials. The ...
- For both the compulsive trader and careful investor: 25 stocks to watch if risk appetite returns; some with upside potential, some notIf the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 29%In the current phase of market volatility, the only solace to be derived is from market history. And history tells us that, just like good ...
- Nvidia-backed AI startup SandboxAQ creates new data to speed up drug discoverySandboxAQ, an AI startup originating from Alphabet's Google and backed by Nvidia, has released a substantial dataset to accelerate drug dis...
- Ahammune Biosciences raises $5 million to fund novel vitiligo therapyThe funding will enable the company in conducting Phase II human clinical trials for its potential drug candidate for vitiligo - an autoimm...
- PMS funds that helped HNIs survive September shockAt least 50 PMS funds managed to eke out positive returns during the month, showed data pulled from PMSBazaar
- Cipla, Kemwell Biopharma join hands to develop biosimilarsUnder the terms of the agreement, the joint venture will leverage Cipla and Kemwell’s complementary strengths for end-to-end product develo...
- This firm is hunting for a cancer cureZumutor, the Boston-headquartered startup, which was founded by second-time entrepreneur and former Biocon executive Kavitha Iyer Rodrigues...
- IIL's Rs 40-crore R&D facility becomes operationalThe research and development (R&D) facility is set up by OAT and IIL Laboratories Ltd, a joint venture company between IIL and Japanese fir...
- Biosimilar products development gets a USFDA norms boostA biosimilar is a product that is similar to a biologic, which in turn is any drug produced through a biological route rather than chemical...
- US drugmaker Eli Lilly, Jubilant Life call off joint ventureUS drugmaker Eli Lilly & Company and Noida-based Jubilant Life Sciences have called off their equal drug-discovery partnership to develop m...
- Shasun inks JV with US-based Nanoparticle BiochemShasun Pharmaceuticals Ltd has entered into a joint venture with US based Nanoparticle Biochem Inc to explore opportunities in the field of...
- TCG Lifesciences, Pfizer ink drug research pactTCG Lifesciences, the Rs 400-crore clinical research organisation (CRO) venture of the Chatterjee Group, has entered into an exclusive coll...
- Dr Reddy’s eyes new ops for Perlecan candidatesDrug-maker Dr Reddy’s Laboratories will stop innovative drug research at Perlecan Pharma, its wholly-owned subsidiary, due to a virtual fre...
- Eli Lilly, Jubilant Organosys form R&D joint ventureEli Lilly and Jubilant Organosys have formed a 50:50 R&D joint venture (JV) to develop molecules across several thereupatic areas.
- 'Pullout to hurt investor confidence'This week, sources told ET that ICICI Venture and Citigroup Venture are in talks with Dr Reddy’s to pull out their investment in Perlecan o...
- PEs may exit Dr Reddy's R&D unitICICI Venture Funds and Citigroup Venture Capital are likely to pull out their investment in Dr Reddy’s Laboratories’ drug research company...
- DRL stops work on new diabetes drugIndia’s largest drug maker, Dr Reddy’s Laboratories, has stopped further development of a new drug aimed at treating diabetes and obesity.
- UPL to form speciality products JV with Japanese cosAgrochemicals major United Phosphorus (UPL) will set up a joint venture company with Japanese players Ishihara Sangyo Kaisha (ISK) and Mits...
Load More
